Recent Advances in the Discovery of CK2 Inhibitors

Mustafa A Al-Qadhi1, Tawfeek A A Yahya2, Hala B El-Nassan3

  • 1Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, 18084 Sana'a, Yemen.

ACS Omega
|May 20, 2024
PubMed

Insights

Protein kinase CK2 (casein kinase 2) is crucial in cellular processes and cancer. New CK2 inhibitors, particularly allosteric and dual types, offer improved selectivity over current ATP-competitive drugs, potentially reducing side effects.

Area of Science:

  • Biochemistry
  • Enzymology
  • Medicinal Chemistry

Background:

  • Protein kinase CK2 (casein kinase 2) is a key enzyme regulating numerous cellular functions through phosphorylation.
  • Aberrant CK2 activity is implicated in the progression of various cancers.
  • Existing CK2 inhibitors, primarily ATP-competitive, face challenges with off-target effects.

Purpose of the Study:

  • To review recent advancements in the design of CK2 inhibitors.
  • To highlight the development of allosteric and dual CK2 inhibitors as potential anticancer agents.
  • To discuss strategies for overcoming limitations of current ATP-competitive CK2 inhibitors.

Main Methods:

  • Literature review of research published in the last five years.
  • Analysis of novel chemical structures and design strategies for CK2 inhibitors.
  • Evaluation of inhibitor selectivity and specificity profiles.

Main Results:

  • Significant progress in developing selective CK2 inhibitors, including allosteric and dual-acting compounds.
  • Demonstration of enhanced specificity and reduced off-target effects compared to ATP-competitive inhibitors.
  • Identification of promising therapeutic candidates for cancer treatment.

Conclusions:

  • Allosteric and dual CK2 inhibitors represent a promising next generation of anticancer therapeutics.
  • These novel inhibitors offer improved selectivity and specificity, potentially leading to safer and more effective cancer treatments.
  • Continued research in CK2 inhibitor design is crucial for advancing cancer therapy.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K